"Lagging Indicators": Is There A "Drug Lag" Between U.S. And Europe?
This article was originally published in Pharmaceutical Approvals Monthly
The "drug lag" is back. The term - biopharma industry shorthand for the belief that new drugs reach the market faster in other countries (especially in Europe) than they do the in U.S. - was a common refrain in the late 1980s and early 1990s, and the Prescription Drug User Fee Act of 1992 was intended in part to address the perception that U.S. consumers suffered while FDA reviews dragged on
You may also be interested in...
Perceptions that FDA is more conservative in its approval standards than its European regulatory counterpart are misguided and largely overblown, Office of New Drugs Director John Jenkins said
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011